PUMA expression is significantly reduced in human cutaneous melanomas
Related Experiment Video
Updated: Aug 19, 2026

Pharmacologic Induction of Epidermal Melanin and Protection Against Sunburn in a Humanized Mouse Model
Published on: September 7, 2013
Alison M Karst1, Derek L Dai, Magdalena Martinka
1Department of Medicine, Division of Dermatology, University of British Columbia, Vancouver, BC V6H 3Z6, Canada.
Abstract:
Cutaneous malignant melanoma is an aggressive form of skin cancer, characterized by strong chemoresistance and poor patient prognosis. The molecular mechanisms underlying its resistance to chemotherapy remain unclear but are speculated to involve the dysregulation of apoptotic pathways. In this study, we sought to determine whether PUMA (p53 upregulated modulator of apoptosis) contributes to human melanoma formation, tumor progression, and survival. We used tissue microarray and immunohistochemistry to examine PUMA expression in 107 primary melanomas, 51 metastatic melanomas, and 64 dysplastic nevi. Here we report that PUMA expression is significantly weaker in primary melanomas compared to dysplastic nevi (P<0.0001), and is further reduced in metastatic melanomas compared to primary tumors (P=0.001). We show that weak PUMA expression in melanoma correlates with poorer overall and disease-specific 5-year survival (P<0.005 and P<0.001, respectively) of melanoma patients and that PUMA expression in tumor tissue is an independent predictor of both overall and disease-specific 5-year survival (P=0.05). Additionally, we show that exogenous PUMA expression in human melanoma cell lines (both wild type and mutant p53) results in significant apoptotic cell death. Our results suggest that PUMA expression may be an important prognostic marker for human melanoma and that adenoviral delivery of PUMA sensitizes melanoma cells to apoptosis.
Insights
Reduced PUMA (p53 upregulated modulator of apoptosis) expression correlates with poorer survival in melanoma patients. Restoring PUMA levels induces cancer cell death, suggesting its potential as a prognostic marker and therapeutic target.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Research
Background:
- Cutaneous malignant melanoma is an aggressive skin cancer with poor prognosis and chemoresistance.
- Dysregulation of apoptotic pathways is implicated in melanoma chemoresistance.
- The role of PUMA (p53 upregulated modulator of apoptosis) in melanoma is not well understood.
Purpose of the Study:
- To investigate the role of PUMA in human melanoma formation, progression, and survival.
- To determine if PUMA expression levels correlate with patient prognosis.
- To assess the therapeutic potential of PUMA in melanoma.
Main Methods:
- Tissue microarray and immunohistochemistry used to analyze PUMA expression in 107 primary melanomas, 51 metastatic melanomas, and 64 dysplastic nevi.
- Statistical analysis to correlate PUMA expression with patient survival.
- Exogenous PUMA expression induced in human melanoma cell lines to evaluate apoptotic response.
Main Results:
- PUMA expression was significantly lower in primary melanomas than in dysplastic nevi (P<0.0001).
- PUMA expression was further reduced in metastatic melanomas compared to primary tumors (P=0.001).
- Weak PUMA expression correlated with poorer overall and disease-specific 5-year survival (P<0.005 and P<0.001, respectively) and was an independent predictor of survival (P=0.05).
- Exogenous PUMA expression induced significant apoptotic cell death in melanoma cell lines.
Conclusions:
- PUMA expression is reduced during melanoma progression and correlates with poor patient survival.
- PUMA may serve as a valuable prognostic marker for human melanoma.
- Adenoviral delivery of PUMA sensitizes melanoma cells to apoptosis, indicating potential therapeutic applications.
Related Concept Videos
Abnormal Proliferation
Pigmentation
Melanin occurs in two primary forms: eumelanin that provides black and brown pigment and pheomelanin that provides red color. Dark-skinned individuals produce more melanin than those with pale...
Skin Cancer
Basal Cell Carcinoma (BCC): BCC is the most common type of skin cancer, accounting for about 80% of cases. It typically develops in...

